Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial for those ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has presented new data which shows Gazyva is superior to its established Rixtuxan/Mabthera in treating follicular lymphoma (FL). Rituxan/MabThera is one of Roche's biggest sellers, earning ...

Roche HoldingsRHHBY announced that the FDA has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV). Per the company, Rituxan is the first ...

Roche Holding AG RHHBY announced that the FDA approved the label expansion of Rituxan (rituximab). The agency approved the drug, in combination with glucocorticoids, for the treatment of two rare ...

Obinutuzumab for induction and maintenance provides significantly higher PFS than rituximab, the current standard of care for follicular lymphoma (FL). But an editorial cautions it's too soon to tell.

Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.

The Rituximab (Roche) Market in China 2018-2022 - Rituximab Recorded a Revenue of CHF 7.388 Billion in 2017 - ResearchAndMarkets.com July 31, 2018 09:49 AM Eastern Daylight Time ...

Roche has secured approval from the European Commission (EC) for Columvi (glofitamab) plus gemcitabine and oxaliplatin (GemOx) combo to treat adults with relapsed or refractory (R/R) diffuse large ...

Rituxan/MabThera is one of Roche's biggest sellers, earning around $7 billion a year across a variety of indications, including FL and chronic lymphocytic leukemia (CLL).